Zach Newman

Zach Newman is a science advisor and registered patent agent in Goodwin’s Life Sciences practice group.

Dr. Newman works on intellectual property matters for clients in the biotechnology space, including patent prosecution, due diligence, patent portfolio reviews, and patentability and freedom-to-operate analyses. Biotechnology areas of focus include molecular and cellular biology-based technologies, immunotherapy, antibody platforms and therapies, gene editing technologies, and vaccine therapies. As a registered patent agent with the United States Patent and Trademark Office (USPTO), his practice is limited to matters and proceedings for the USPTO.

Prior to joining Goodwin, Dr. Newman was a patent agent at Fenwick & West LLP. Before a career in law, he performed doctoral research with a focus in immunology at UC Berkeley, specifically exploring the regulation of toll-like receptors within the innate immune system.

Dr. Newman performed his doctoral work in the laboratory of Dr. Greg Barton in the Molecular And Cell Biology department at UC Berkeley. His research focused on characterizing a novel potential regulatory mechanism of nucleic acid sensing Toll‑Like Receptors, with a focus on the potential role played in autoimmune diseases such as lupus. As part of his research, he employed a variety of cutting‑edge techniques such as CRISPR/Cas9 gene editing, 4sU RNA labeling, and ribosome profiling. His work in graduate school resulted in authorship on peer-reviewed articles in Proceedings of the National Academy of Sciences, Nature Immunology, and eLife.

Prior to graduate school, Dr. Newman was a staff research associate at UCSF in the laboratory of Dr. Jeff Cox where he helped establish a novel system to explore the difficult biology of tuberculosis, specifically large-scale protein pulldowns to generate mass spectrometry interaction maps.